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Abstract
Introduction Bone metastatic disease is a major cause of pain and decreased quality of life in patients with cancer. In
addition to systemic therapy and pain control with narcotic analgesics, standard local treatments include palliation
with radiation therapy and surgery. However, 20–30 % of patients do not respond to conventional treatments,
increasing the interest in alternative therapies. We present the results of a new minimally invasive technique in the
treatment of bone metastases.
Methods Twenty-nine patients affected by painful bone metastases were treated with electrochemotherapy (ECT)
from July 2009 to July 2011; the mean age was 60 years (range 37–87); 21 patients received a previous ineffective
local treatment; the appendicular skeleton was affected in 15 patients while in 14 patients other sites were involved.
ECT was performed using the Cliniporator Vitae under fluoroscopy or CT guidance depending on the site of the
lesion. Clinical response was assessed using VAS scale and objective tumour response was evaluated according to the
MD Anderson criteria for bone metastases.
Results All patients well tolerated the procedure and no intraoperative or postoperative complications were observed.
At a mean follow-up of 7 months, 24 patients were available for evaluation. 84 % of the patients (20 out of 24)
referred improvement of pain C50 % with reduction of narcotics consumption. Radiographic evaluation after
3 months in 20 evaluable patients, showed ‘‘partial response’’ in 1 patient, ‘‘stable disease’’ in 17 and ‘‘progression’’
in two cases.
Discussion Results reported in this study demonstrated ECT to be safe and feasible in the treatment of painful bone
metastases even when other previous treatments were ineffective. Pain and disease progression control was achieved
in the majority of the patients with consequent improvement of quality of life.
Conclusion ECT should be considered a new feasible tool in the treatment of bone metastases in place or in
combination with standard treatments; further developments are required to extend the use of this technique to spine
metastases.
Introduction
Prolonged cancer survival achieved with advances in
medical therapies has increased significantly the number of
patients with painful bone metastases, requiring new
treating modalities in order to improve quality of life [1–3].
Surgery treatment is often required to prevent or treat
pathologic fractures of long bones or to release spinal cord
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compression in case of spine metastases [4] with the aim of
function preservation and quick mobilisation of the patient.
When surgery is not indicated or in completion to surgery,
radiation therapy in fractionated doses (8 Gy/1f or 30 Gy/
10f) is considered the standard treatment but could be
ineffective in 30–50 % of the cases.
Other minimally invasive technique are available (ra-
diofrequency thermal ablation or selective arterial
embolization) but with similar or worst in term of local
progression or pain control. [1].
Electrochemotherapy (ECT) refers to the combination of
chemotherapy and local delivery of electric pulses to the
tumour nodule. Electric pulses induce cell membrane
electroporation to increase drug diffusion into the cell and
its cytotoxicity; bleomycin is the drug used for ECT as its
activity in vivo is increased [80 times following mem-
brane electroporation. ECT has proven effective in the
treatment of metastases from solid tumours of any histol-
ogy located to the skin or subcutaneous tissue. The mul-
ticenter study ESOPE (European Standard Operating
Procedure for ECT) demonstrated that ECT may achieve
an objective response rate of 85 % (74 % complete
response rate) in treated tumour lesions [5, 6]. Furthermore,
in nodules undergoing complete response, long-term his-
tology shows that no residual tumour cells are detected
locally [7–9].
Following extensive clinical studies confirming safety
and efficacy of ECT, clinicians and researchers developed
new strategies to extend its use to the treatment of non-
superficial tumours [10].
Encouraging results reported in preclinical studies and
in animal models demonstrated electroporation does not
alter bone mineral structure, regenerative activity and
mechanical competence [11–13] providing preclinical
basis for use of ECT in the treatment of metastasis to bone
in patients.
As a first in human application of ECT in the treatment
of bone metastases, this prospective study was designed
and conducted with the primary endpoints of feasibility and
safety.
Patients and methods
A prospective, single centre, single arm Phase II clinical
trial was approved by the ethical committee of our insti-
tution (Prot.n.12458/15.05.2009—ES2IOR). All patients
gave their written, informed consent to participate in the
study.
Eleven patients enrolled in the study were grouped in
Group 1 from July 2009 to July 2011. After completing the
treatment of patients of Group 1, besides that, a second
Group of 18 patients (Group 2) with tumour larger than
6 cm was evaluated (protocol amendment).
Study primary endpoints were feasibility and safety of
ECT when applied to metastases to the bone; secondary
endpoints were patients’ clinical outcome and changes of
metastases at imaging investigations.
Feasibility was assessed by evaluating the possibility of
reliably inserting electrodes percutaneously in bone,
according to a predefined geometry to ensure proper elec-
troporation of cell membranes in the bone metastasis,
hence to successfully complete the procedure.
For safety, all adverse events, after treatment and at
follow-up, were recorded and evaluated according to
CTCAE criteria (Common Toxicity Criteria for Adverse
Events). We considered severe events those that would
require substantial medical intervention in consequence of
the local treatment with ECT.
Inclusion criteria were histologically proven involve-
ment of appendicular skeleton by metastatic carcinoma or
melanoma; maximum metastasis length 6 cm; no local
treatment in previous 3 months; life expectancy
[3 months; Karnofsky 70 %.
To assess tumour volume/density, all patients underwent
standard X-ray, MRI or CT scan, with contrast enhance-
ment, at presentation. Patients with multiple lesions were
considered for enrolment if a target symptomatic lesion
could be identified. Each case was discussed at institutional
multidisciplinary meeting.
Exclusion criteria were patients with pathological frac-
tures, with symptomatic or rapidly progressive visceral
disease, known allergic reaction to bleomycin, cumulative
bleomycin dose exceeding 250 l/m2, abnormal haemosta-
sis, chronic renal dysfunction, arrhythmia, pregnancy or
lactation.
Protocol foresaw follow-up visits at 2 months for clin-
ical evaluation and at 3 months for CT scan. Further
clinical evaluations were scheduled at 6 months and
1 year. Clinical response included evaluation of change in
pain by the VAS scale; use of pain killers, quality of nights
sleep and return to daily activities [14].
Objective tumour response was evaluated according to
the MD Anderson (MDA) criteria that define four different
categories of response (CR-complete response, PR-partial
response, PD-progressive disease and SD-stable disease)
[15]. Radiological and clinical evaluations were performed
by two investigators, GB and LC.
Demographic, tumour specifications and site of
involvement regarding the two groups are reported in
Table 1.
Tumour cell electroporation was performed using the
Cliniporator VITAE (IGEA S.p.A., Carpi, Italy). I 20 cm
insulated needle electrodes (3 or 4 cm active tip) were
drilled into the healthy bone to surround the metastases
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(Fig. 1). The number of needles used for each session
varied from 6 to 8 according to tumour size and geometry.
For electrode insertion, fluoroscopy guidance was used in
16 patients with peripheral skeleton involvement (7 femur,
5 tibia, 3 humerus, 1 scapula), while in other 14 patients
with pelvic (9), sacral (4), femoral (1) lesions CT guiding
was preferred. The choice of imaging technique used for
electrode insertion was left at the discretion of the inves-
tigators, based on lesion accessibility.
ECT procedures were performed according to ESOPE
study; briefly: 8 pulses of 1000 V/cm were delivered
between each couple of electrodes to homogeneously cover
the metastases with local electric field ([350 V/cm) to
induce cell membrane electroporation. Bleomycin, 15 l/m2
(Bleomycin Nippon Kayaku, Sanofi Aventis, Milan, Italy),
was administrated intravenously in 8 min bolus before
applying the electric pulses. This time is required to allow
the distribution of the drug in all interstitial spaces at an
effective concentration. The treatment has to be completed
within 28 min from bleomycin injection [16]. As per pro-
tocol, patients could undergo up to 2 ECT treatments,
4 weeks apart, based on the possibility of increasing local
disease control [6]. Further treatments were offered to
patients that had significant benefit from ECT and had pain
recurrence at the same site.
In 14 patients (48 %), the treatment was completed
under regional anaesthesia and in 16 patients (52 %) under
general anaesthesia. Patients’ general conditions influence
the choice of anaesthesia protocol, when possible regional
anaesthesia was preferred. Type of anaesthesia does not
influence the ECT treatment outcome [6].
Results
Overall 29 patients successfully underwent at least one
ECT procedure and they were discharged from the hospital
the day after ECT treatment without complications. 43
procedures were completed in 29 patients. Mean follow-up
was 7 months (1–22), two patients were lost at follow-up,
nine died because of the disease and 18 were alive with
disease at last follow-up (Fig. 2). No acute side effects
related to bleomycin injection were observed.
Primary outcome
In group 1, the procedure was repeated four times in one
patient, three times in another patient, two times in two
patients and the other seven patients received only one
procedure. Patients receiving more than two ECT treat-
ments did so after completing and exiting the clinical trial
according to study protocol. Further treatments were
Table 1 Demographic, tumour specifications and site of involvement
Group 1 Group 2
Patients 11 18
Gender (M/F) 4/7 6/12









Metastatic sarcoma 0 1
Bladder 0 1












Fig. 1 Schematic representation of electrode insertion in proximal
femur: electrodes and drill; positioning mask on skin surface; bone
metastases in red
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offered to maintain local disease control when other
options were exhausted.
In group 1, femur fracture occurred after the second
treatment showing that repeated electrode insertion weak-
ens the cortical bone. Nevertheless, the metastasis had not
progressed and the fracture treated by endomedullary
nailing healed. Histology of cells recovered at fracture site
was negative for the presence of tumour cells.
Among patients in group 2, 12 patients received a single
ECT treatment, five patients received two treatments and
one patient received three treatments.
In both groups, no life threatening events were associ-
ated with the treatment. Nevertheless, two severe adverse
events that occurred in Group 2 were investigated. A wide
area of necrosis and ulceration, in previously irradiated
skin of proximal tibia, required above knee amputation.
Neurogenic bladder was observed after the third treatment
of a large lesion involving the sacrum. Neurogenic bladder
did not recover spontaneously, and it was deemed related
to local disease progression.
Secondary outcome
In group 1, clinical results were available for eight patients
only. The mean pre-ECT VAS value was 5 (2–10) that,
after ECT lowered to 2 (0–4). Significant pain decrease
(C50 %) was reported by six out of eight patients.
Eight patients diminished the use of pain killers and
improved the quality of night’s sleep; daily activities
ameliorated in six patients in long-term follow-up.
For seven patients, additional diagnostic imaging was
available at more than 3 months follow-up showing partial
response in one patient and stable disease in six patients.
Four patients were dead.
In group 2, clinical results were available for 16 patients
as two patients did not return for follow-up visit. The mean
pre-ECT VAS value was 7 (2–10) and declined to 3 (0–8)
after ECT. Pain decrease C50 % was reported in 14 out of
16 patients.
Diagnostic imaging at more than 3 months follow-up
was available for 13 patients: 11 showing stable disease
and two patients showing progressive disease.
Figure 3 and 4 briefly sum up two CT-guided
procedures and their radiographical results at follow-
up.
Fig. 2 Organogram of patients treated. Group 1 patients per
protocol; Group 2 compassionate treatment. DOD dead of disease,
AWD alive with disease
Fig. 3 a–c A 69-year-old patient: left femoral neck painful bone
metastases, thyroid carcinoma, a CT-guided ECT needles positioning,
coronal plane, b X-ray result at 6 months of follow-up; sclerotic rim
surrounding the lesion: Partial Response (c)
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Discussion
To the best of the authors’ knowledge, this is the first
prospective clinical study on the use of ECT for the
treatment of bone metastasis even if results are reported on
a small number of patients and with the lack of compara-
tive arm.
Extensive evidence on the efficacy of ECT in metastasis
to the skin and subcutaneous tissue of different histological
origins is present in the literature [5, 10].
Preclinical data on the use of ECT for the treatment of
metastases to bone provided the rationale for designing and
conducting this clinical trial [11, 13]. We developed the
procedure to treat ECT patients with bone metastases. The
orthopaedic surgeon can perform the procedure without
difficulties, no complications were experienced during the
operating procedure. ECT can be performed in the prox-
imity of vital structures considered there is no thermal
denaturing effect; furthermore, applied electric pulses have
no damaging effect on nerves and vessels [17, 18]. Treat-
ment was easier to perform in patients with small and
regularly shaped lesions.
Pain relief was achieved in 84 % of patients. Use of pain
killers, quality of night’s sleep and daily activities
improved in 55–73 % of patients. These results are relevant
in this group of patient that already underwent treatments
that proved to be ineffective (radiotherapy and/or SAE).
These patients presented with deteriorate overall health
status or severe co-morbidities and major surgery was not
indicated. Local tumour control (stable disease) was
achieved in most patients; only 10 % of the lesions showed
progression at follow-up.
In patients treated according to protocol one, fracture
that occurred in femur after a second treatment was
explained by the repeated electrode insertion, that led to the
weakening of bone mechanical competence.
In one patient of group 2, severe skin necrosis required
leg amputation. Necrosis and ulceration should always be
considered carefully in patients with poor soft tissue
envelop or in area previously irradiated. We did not
observe systemic toxic effects of bleomycin. Lung toxicity
of bleomycin is well known, this occurs only when the
cumulative dose exceeds 250–300 U much higher than the
dose here used. Previous use of high doses of bleomycin
was an exclusion criteria.
Almost 75 % of metastasis to bone are symptomatic
and require local treatment to improve quality of life and
prevent local disease progression. Except primary sur-
gery, external beam radiotherapy is the main treatment
modality for pain control with a response rate of 70 %
[14, 19]. However, radiation therapy weakens bone
mechanical competence and it affects bone blood supply,
which can lead to post-radiation fracture requiring further
treatment such as resection and reconstruction with a
prosthesis [2].
Other treating modalities have been proposed and
different results are reported according to treatment
type. Goetz et Al. and Gronemeyer reported effective
pain control with radiofrequency ablation (RFA)
(75–95 %). Rossi et al. reported good results in pain-
control using selective arterial embolization (SAE) in
patients affected by highly vascularised metastatic
lesions such as renal cancer metastases. In a series of
107 patients, pain control was achieved in 96 % of the
Fig. 4 a–c A 57-year-old patient: left ischium painful bone metas-
tases, kidney carcinoma, a CT-guided ECT needles positioning and
multiplanar reconstruction, b CT scan at 7 months follow-up; central
necrosis and shrinking of the metastatic lesion: Partial Response (c)
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cases but transient effect was frequent, requiring mul-
tiple treatments [20].
ECT is a new minimally invasive technique easily fea-
sible at the appendicular skeleton and, with more difficul-
ties, to other skeletal sites. Differently from other
techniques, ECT should not be considered an ‘‘ablative’’
procedure, but a ‘‘neoplasm-selective’’ procedure, sparing
healthy tissue from the toxic effect of bleomycin and pre-
serving the mechanical competence of bone [13]. These
characteristics suggest that ECT might be electively used
for early control of isolated metastases to bone, to finally
preserve bone quality, to favour bone reconstruction and
avoid the surgical procedures required to protect bone from
fracture. The results obtained in Group 2 indicate that ECT
can play an important role in patients with advanced dis-
ease and inoperable metastases resulting in immediate pain
relief and improvement in quality of life.
This study shows that the ECT procedure is safe and can
spare patients major surgery. Compared to other ablation
treatments, ECT is minimally invasive, repeatable and
preserves mechanical competence of bone tissue; further-
more, other treatments are possible. Present limit of the
technique is spine metastases treatment, since the vicinity
of the spinal cord and technical limitations of electrode
positioning.
Conclusion
Results reported in this study demonstrated ECT to be a
feasible, safe and effective technique in the treatment of
painful bone metastases of the pelvis and appendicular
skeleton, even when other previous treatments were inef-
fective. Pain and disease progression control was achieved
in the majority of the patients with consequent improve-
ment of quality of life. Further developments are required
to extend the use of this technique to spine metastases.
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